JPWO2019204269A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019204269A5 JPWO2019204269A5 JP2020556877A JP2020556877A JPWO2019204269A5 JP WO2019204269 A5 JPWO2019204269 A5 JP WO2019204269A5 JP 2020556877 A JP2020556877 A JP 2020556877A JP 2020556877 A JP2020556877 A JP 2020556877A JP WO2019204269 A5 JPWO2019204269 A5 JP WO2019204269A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- enzyme
- transgenic
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 38
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- 230000009261 transgenic effect Effects 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108010031676 Kynureninase Proteins 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 102000005447 kynureninase Human genes 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 238000011394 anticancer treatment Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012642 immune effector Substances 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 15
- 102220577240 Density-regulated protein_K93Y_mutation Human genes 0.000 description 2
- 239000004229 Alkannin Substances 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102220577161 Density-regulated protein_D67Y_mutation Human genes 0.000 description 1
- 102220540161 F-box only protein 8_I51M_mutation Human genes 0.000 description 1
- 102220582722 Heparan sulfate glucosamine 3-O-sulfotransferase 2_E90A_mutation Human genes 0.000 description 1
- 102220512368 Myosin-10_S60N_mutation Human genes 0.000 description 1
- 102220472510 Protein ENL_Y47L_mutation Human genes 0.000 description 1
- 102220529113 Receptor expression-enhancing protein 5_K64N_mutation Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102220598898 Thiamine transporter 1_I48F_mutation Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 102220377334 c.289A>G Human genes 0.000 description 1
- 102220350170 c.295G>T Human genes 0.000 description 1
- 102220354206 c.41A>G Human genes 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102220198533 rs1057520077 Human genes 0.000 description 1
- 102200006121 rs1060501260 Human genes 0.000 description 1
- 102200126544 rs121917836 Human genes 0.000 description 1
- 102220081835 rs145116688 Human genes 0.000 description 1
- 102200066677 rs1554616652 Human genes 0.000 description 1
- 102220271164 rs1555604887 Human genes 0.000 description 1
- 102200082940 rs33936254 Human genes 0.000 description 1
- 102220064941 rs368719191 Human genes 0.000 description 1
- 102200155474 rs397507512 Human genes 0.000 description 1
- 102200011638 rs587777189 Human genes 0.000 description 1
- 102200011636 rs587777191 Human genes 0.000 description 1
- 102200164349 rs63750641 Human genes 0.000 description 1
- 102200037754 rs6493068 Human genes 0.000 description 1
- 102200020878 rs73015965 Human genes 0.000 description 1
- 102220061395 rs786203280 Human genes 0.000 description 1
- 102220173061 rs886050492 Human genes 0.000 description 1
- 102220192067 rs886057201 Human genes 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658261P | 2018-04-16 | 2018-04-16 | |
| US62/658,261 | 2018-04-16 | ||
| PCT/US2019/027623 WO2019204269A1 (en) | 2018-04-16 | 2019-04-16 | Human kynureninase enzymes and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521777A JP2021521777A (ja) | 2021-08-30 |
| JP2021521777A5 JP2021521777A5 (https=) | 2022-04-07 |
| JPWO2019204269A5 true JPWO2019204269A5 (https=) | 2022-04-07 |
| JP7432851B2 JP7432851B2 (ja) | 2024-02-19 |
Family
ID=68240288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556877A Active JP7432851B2 (ja) | 2018-04-16 | 2019-04-16 | ヒトキヌレニナーゼ酵素及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11648272B2 (https=) |
| EP (1) | EP3781179A4 (https=) |
| JP (1) | JP7432851B2 (https=) |
| KR (1) | KR102862473B1 (https=) |
| CN (1) | CN112218644A (https=) |
| AR (1) | AR115051A1 (https=) |
| AU (1) | AU2019257340B2 (https=) |
| BR (1) | BR112020020772A2 (https=) |
| CA (1) | CA3096549A1 (https=) |
| CL (1) | CL2020002650A1 (https=) |
| CO (1) | CO2020013050A2 (https=) |
| EA (1) | EA202092487A1 (https=) |
| IL (1) | IL277765B1 (https=) |
| MX (1) | MX2020010932A (https=) |
| SG (1) | SG11202009559RA (https=) |
| TW (1) | TWI827593B (https=) |
| WO (1) | WO2019204269A1 (https=) |
| ZA (1) | ZA202006077B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| JP7080053B2 (ja) * | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| US11542486B2 (en) | 2016-03-02 | 2023-01-03 | Board Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| CA3154817A1 (en) * | 2019-10-17 | 2021-04-22 | James Nolan | Pegylated kynureninase enzymes and uses thereof for the treatment of cancer |
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| WO2003065984A2 (en) | 2002-02-01 | 2003-08-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease |
| CN1330774C (zh) | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| WO2004094409A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20120085209A (ko) * | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| EP2753315B1 (en) | 2011-09-07 | 2017-03-01 | Deutsches Krebsforschungszentrum | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| JP7080053B2 (ja) * | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| US11542486B2 (en) | 2016-03-02 | 2023-01-03 | Board Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
-
2019
- 2019-04-16 CA CA3096549A patent/CA3096549A1/en active Pending
- 2019-04-16 US US16/385,562 patent/US11648272B2/en active Active
- 2019-04-16 AU AU2019257340A patent/AU2019257340B2/en active Active
- 2019-04-16 JP JP2020556877A patent/JP7432851B2/ja active Active
- 2019-04-16 KR KR1020207032702A patent/KR102862473B1/ko active Active
- 2019-04-16 EA EA202092487A patent/EA202092487A1/ru unknown
- 2019-04-16 TW TW108113281A patent/TWI827593B/zh active
- 2019-04-16 WO PCT/US2019/027623 patent/WO2019204269A1/en not_active Ceased
- 2019-04-16 EP EP19789290.4A patent/EP3781179A4/en active Pending
- 2019-04-16 MX MX2020010932A patent/MX2020010932A/es unknown
- 2019-04-16 BR BR112020020772-1A patent/BR112020020772A2/pt unknown
- 2019-04-16 SG SG11202009559RA patent/SG11202009559RA/en unknown
- 2019-04-16 AR ARP190101000A patent/AR115051A1/es unknown
- 2019-04-16 CN CN201980025530.2A patent/CN112218644A/zh active Pending
-
2020
- 2020-09-30 ZA ZA2020/06077A patent/ZA202006077B/en unknown
- 2020-10-03 IL IL277765A patent/IL277765B1/en unknown
- 2020-10-14 CL CL2020002650A patent/CL2020002650A1/es unknown
- 2020-10-19 CO CONC2020/0013050A patent/CO2020013050A2/es unknown
-
2023
- 2023-04-06 US US18/296,687 patent/US12144828B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3171268B2 (ja) | 治療抗体基融合タンパク質 | |
| ES2259030T3 (es) | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. | |
| JP2016533753A5 (https=) | ||
| JP7037884B2 (ja) | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン | |
| JPH02503867A (ja) | Ｉｌ‐２レセプター特異的キメラ抗体 | |
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| RO119721B1 (ro) | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale | |
| JP2021521777A5 (https=) | ||
| EA005005B1 (ru) | ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| ES2660776T3 (es) | Tratamiento para la artritis reumatoide | |
| JP4175489B2 (ja) | 改変型超抗原と標的探索化合物との結合体及び該結合体の使用 | |
| JP2001526040A (ja) | ピヒア酵母発現系を用いる抗血管形成タンパク質：エンドスタチン、アンジオスタチンまたはレスチンの生産方法 | |
| JP2008535475A5 (https=) | ||
| CN113461825B (zh) | 一种抗pd-l2纳米抗体及其应用 | |
| CN109414426A (zh) | 使用精氨酸耗竭剂的组合癌症免疫疗法 | |
| JP2021521777A (ja) | ヒトキヌレニナーゼ酵素及びその使用 | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| US12258408B2 (en) | Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus | |
| CN111087465B (zh) | 一种针对密蛋白6的抗体偶联药物及应用 | |
| JPWO2019204269A5 (https=) | ||
| WO1999061057A2 (en) | Molecules targeting cd40 and tumor cells | |
| JP2021506320A5 (https=) | ||
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| JP2008502323A5 (https=) | ||
| JPH05304987A (ja) | ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤 |